| __timestamp | Amicus Therapeutics, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 10337679 |
| Thursday, January 1, 2015 | 47269000 | 18187286 |
| Friday, January 1, 2016 | 71151000 | 24758063 |
| Sunday, January 1, 2017 | 88671000 | 23666957 |
| Monday, January 1, 2018 | 127200000 | 30099855 |
| Tuesday, January 1, 2019 | 169861000 | 64947625 |
| Wednesday, January 1, 2020 | 156407000 | 186363444 |
| Friday, January 1, 2021 | 192710000 | 272611040 |
| Saturday, January 1, 2022 | 213041000 | 358782000 |
| Sunday, January 1, 2023 | 275270000 | 409864000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting SG&A spending patterns. From 2014 to 2023, Amicus Therapeutics increased its SG&A expenses by over 1,200%, peaking in 2023. Meanwhile, Intra-Cellular Therapies saw a staggering rise of nearly 3,900% in the same period, reflecting its aggressive market expansion strategy. Notably, in 2020, Intra-Cellular Therapies surpassed Amicus in SG&A spending, marking a pivotal shift in their financial strategies. These trends highlight the dynamic nature of the biotech industry, where companies must balance innovation with operational efficiency to thrive. As these two companies continue to evolve, their SG&A strategies will likely play a crucial role in shaping their future trajectories.
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and Intra-Cellular Therapies, Inc.
Alnylam Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.